Before You Build the Campaign, Build the Evidence Map
There's a version of the product launch process that goes like this: someone spots a trend, the brand team gets excited, marketing develops a concept, legal reviews the label copy at the last minute, and everyone hopes the claims hold up if anyone looks closely.
It happens constantly. And it's almost entirely backwards.
The brands that build durable positions in health and wellness — the ones whose claims survive regulatory scrutiny, earn consumer trust, and hold up when the category gets crowded — don't start with the campaign. They start with an honest reckoning with what their evidence actually supports. The marketing is the last thing they build, not the first.
That's the core of how we think about claims strategy at Parallaxis. And right now, in 2026, there are three categories that illustrate exactly why this sequence matters — and what goes wrong when it's skipped.
Gut health: when the science is real but the claim language has outrun it
Gut health is a category with genuine, serious, and rapidly developing scientific foundations. Peer-reviewed publications are now linking gut dysbiosis to metabolic health, immunity, mental health, and chronic inflammation Who What Wear — positioning the microbiome as a foundational system rather than a niche interest. The category deserves the attention it's getting.
The problem is that the claim language has run well ahead of what most individual products can actually substantiate.
"Gut healthy." "Supports your microbiome." "Prebiotic." These phrases have become so ubiquitous that brands use them almost reflexively — and they've become a primary target for plaintiff attorneys as a result. There has been a surge of class action activity around functional claims like "prebiotic" and "gut healthy," where plaintiffs argue dose-insufficiency or offsetting ingredients make the claims misleading. Armstrongteasdale
The regulatory picture adds further complexity. In the EU, the EFSA has maintained its long-held stance that all gut-related claims must be backed by causal and mechanism-relevant evidence, and frameworks for postbiotics specifically remain unclear. New Food Magazine In Australia, the TGA's permitted indications framework means that even well-intentioned gut health claims need to map to an approved indication with evidence to match.
The evidence map question in gut health requires precision at a level most brands haven't thought through: which specific strain, at which dose, in which population, producing which measurable outcome? "Supports digestion" is not a claim strategy. It's a placeholder that creates exposure without creating value.
Longevity: when the word is everywhere and the definition is nowhere
"Longevity" has become one of the most commercially powerful words in wellness. It's on supplements, skincare, nutrition products, and med-tech devices. It's emotionally resonant, aspirational, and almost completely undefined from a regulatory standpoint.
That undefined status is precisely the trap.
In the US, neither the FDA nor the FTC has established a regulated definition for "longevity" as a claim. Brands can use the word without pre-approval — which feels like freedom, but functions more like a false floor. The substantiation requirement doesn't disappear because the claim is vague. The FTC's standard of competent and reliable scientific evidence applies regardless of how a claim is categorised. Every implied benefit that a reasonable consumer reads into the word "longevity" — living longer, ageing better, reversing biological decline — still needs evidence standing behind it.
In Australia, the architecture is more explicit. Most supplements are regulated by the TGA as listed medicines, operating within a framework of around 778 permitted indications. "Supports healthy longevity" doesn't exist on that list. You're working with what's there — energy production, general wellbeing, specific antioxidant functions — and you need to hold evidence supporting those indications at time of listing. The NMN story is instructive: one of the most talked-about longevity ingredients globally only received TGA approval as a permissible ingredient in December 2025. The first approved product can make claims about energy support. It cannot promise cellular rejuvenation.
The evidence map question in longevity is brutally simple: what specific mechanism does your product affect, in what specific population, with what quality of human evidence? The category word gets you noticed. The specific, defensible answer to that question is what keeps you out of trouble.
Neurowellness: when the trend is real and the claim is almost impossible
Neurowellness — regulating the nervous system to support whole-body health, resilience, and recovery — has been named the top wellness trend for 2026 by the Global Wellness Summit. Global Wellness Summit The cultural momentum is undeniable. Sleep tracking made nervous system dysregulation visible to mainstream consumers. Burnout made it personal. And now a wave of products, devices, and supplements are positioning themselves as solutions.
Here's the claim problem: "regulates your nervous system" is not a structure/function claim. It's a therapeutic claim in most regulatory frameworks. And the gap between what the neurowellness narrative promises and what a supplement or consumer device can actually say on its label is significant.
In the US, structure/function claims must describe the effect of a nutrient on the structure or function of the body — not imply treatment of a condition or regulation of a physiological system in ways that read as therapeutic. "Supports healthy stress response" operates differently than "regulates nervous system activity." The first is available territory; the second invites scrutiny. Consumer-grade neurostimulation devices marketed without rigorous clinical trial evidence are already drawing attention, with meta-analyses showing mixed results and researchers emphasising the need for qualified professional oversight. Our Healtho
For supplement brands specifically, the neurowellness opportunity sits in specific, well-evidenced ingredients that map to permitted or substantiatable function claims: magnesium and its role in normal nervous system function, ashwagandha's evidence base around cortisol and perceived stress, L-theanine and its studied effects on relaxation without sedation. These are real, defensible, and increasingly relevant to a consumer who wants to feel calmer without being told a product is a medical intervention.
The evidence map question in neurowellness is really a positioning question: are you making a wellness claim, a function claim, or sliding into therapeutic territory? Knowing where your evidence sits — and being honest about which side of that line it supports — is the difference between a claim that works and one that doesn't.
What the map actually looks like in practice
Across all three categories, the pattern is the same. There's a legitimate scientific conversation happening. There's a growing consumer appetite. And there's a widening gap between the language being used in marketing and the language that evidence and regulation actually support.
The way we approach this at Parallaxis is to map the evidence before the claim, not after. That means understanding, for a given product: what is the quality and consistency of the human evidence base? Which specific outcomes does it support, in which populations? What regulatory pathway applies in each target market, and what claim types are available within it? What are the enforcement signals in this category right now?
None of this is exotic. It's methodical. But it requires doing the work before the brief lands on the marketing team's desk — not during the legal review of the finished packaging.
The three categories above aren't cautionary tales. They're live examples of what happens when a market moves faster than its evidence base — and of the genuine opportunity that exists for brands willing to do the work properly. In longevity, gut health, and neurowellness, the science is real. The consumer demand is real. The regulatory risk is real too.
The brands that get all three right will still be standing when the next wave of scrutiny arrives. The ones who borrowed the category language without the evidence to back it up won't.
Parallaxis helps health and wellness brands build evidence strategy before the brief — mapping what's claimable, what's defensible, and what needs more work before it goes on a label. If you're navigating any of these categories, we'd be glad to talk.